Crystals of taxane derivative and process for their production

Details Crystals of taxane derivative and process for their production Crystals of taxane derivative and process for their production

2002-11-29

2008-08-12

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S283700

Reexamination Certificate

active

07410980

ABSTRACT:
A crystal of (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-9,10-[(1S)-2-(dimethylamino)ethylidenedioxy]-5,20-epoxy-1-hydroxytax-11-en-13-yl (2R,3S)-3-(tert-butoxycarbonylamino)-3-(3-fluoro-2-pyridyl)-2-hydroxypropionate, which has characteristic peaks at diffraction angles (2θ) of 6.2°, 10.3°, 10.7°, 11.4°, and 12.0° in a powder X-ray diffraction pattern, and a method for preparing the aforementioned crystal, which comprises the step of performing crystallization by using an organic solvent selected from the group consisting of a ketone type solvent, a nitrile type solvent, and a mixture thereof, or a mixture of said organic solvent and water.

REFERENCES:
patent: 6075140 (2000-06-01), Terasawa et al.
patent: 6184395 (2001-02-01), Singh et al.
patent: 6677456 (2004-01-01), Soga et al.
patent: 2002/0143178 (2002-10-01), Soga et al.
patent: 0826688 (1998-03-01), None
patent: 2000-159757 (2000-06-01), None
patent: 96/33998 (1996-10-01), None
patent: 01/27115 (2001-04-01), None
patent: 02/070512 (2002-09-01), None
Haleblian et al., “Pharmaceutical Applications, etc.,” J of Pharmaceutical Sciences 58 (8), 1969, pp. 911-929.
Chemical & Engineering News, Feb. 2003, pp. 32-35.
Brittain et al., “Polymorphism in Pharmaceutical Solids” NY: Marcel Dekker, Inc., 1999, pp. 1-2, 185.
U.S. Pharmacopia #23, National Formulary #18, 1995, pp. 1843-1844.
Muzaffar et al., “Polymorphism and Drug Availability”, J of Pharmacy (Lahore), 1979, 1(1), 59-66.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23 (6), 315-329.
Wall et al., “Pharmacuetical Applications, etc.,” Pharmaceutical Manufacturing, 1986, 33-42.
Taday et al., “Using Terahertz Pulse, etc.,” J of Pharmaceutical Sciences, 92 (4), 2003. 831-838.
Doelker, Crystalline Modifications, etc., Ann. Pharm. Fr. 2002, 60:161-176 (and english translation pp. 1-39).
Otsuka et al., “Effect of Polymorphic, etc.,” Chem. Pharm. Bull. 47(6):852-856 (1999).
Ulicky et al., “Comphrehensive Dictionary of Physical Chemistry” NY: PTR Prentice Hall, 1992, p. 21.
Bernstein et al., “Polymorphism in Molecular Crystals”, Oxford: Clarendon Press, 2002, pp. 117, 118, 272 and 273.
Davidovich et al., “Detection of, etc.,” American Pharmaceutical Review, IN: Russell Pub., 2004, 7(1), pp. 10, 12, 14, 16 and 100.
Caira, “Crystalline Polymorphism of Organic, etc.,” Topics in Current Chemistry, 198, Berline Heidelberg: Springer Verlag, 1998, pp. 164-208.
T. Ishiyama et al., “New Highly Active Taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 2”, Bioorganic & Medicinal Chemistry Letter, vol. 12, No. 20, pp. 2815-2819 (2002).

Affiliated with

Also associated with

Rating

Crystals of taxane derivative and process for their production does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystals of taxane derivative and process for their production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystals of taxane derivative and process for their production will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4001222